Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – ...

Teladoc Health, Inc. faces challenges with low utilization and operating losses, but a new CEO aims to revitalize the company ...

Oppenheimer maintained Teladoc Health with an Outperform, but lowered the price target from $21 to $17 following the print. According to Benzinga Pro, the stock is down on heavy trading volume ...

Ultimately, these developments have translated into a broad slowdown that helps explain Teladoc's stock-price weakness. In ...

Teladoc thrived during much of the pandemic, but the company's financial results and stock price fell drastically as it receded. Its shares are now below their pre-pandemic levels. Can Teladoc ...

Ultimately, these developments have translated into a broad slowdown that helps explain Teladoc's stock-price weakness. In the third quarter, Teladoc's revenue declined by 3% year over year ...

Was Teladoc Health (NYSE ... Long-term investors with an appetite for risk should consider the stock, especially as its share price remains below its pre-pandemic levels. Risk-averse investors ...

Barclays raised the firm’s price target on Teladoc (TDOC) to $12 from $10 and keeps an Overweight rating on the shares. The stock was up 12% on a better than feared Q3 print, the analyst tells ...